

Luxembourg, June 2025

Public

Environmental and Social Data Sheet¹

Overview

Project Name: *MAAT PHARMA (IEU-LS)*
 Project Number: *2024-0783*
 Country: *France*
 Project Description: *The project supports the Promoter's R&D efforts to develop microbiome-based therapies aimed at treating serious diseases by restoring balance to the microbiome, including immune-related conditions and cancer.*

EIA required: no
 Invest EU sustainability proofing required yes
 Project included in Carbon Footprint Exercise²: no

(details for projects included are provided in section: "EIB Carbon Footprint Exercise")

Environmental and Social Assessment

Environmental Assessment

The Promoter is a clinical-stage biopharmaceutical company focused on developing new therapies that harness the human gut microbiome to address unmet medical needs, including immune-related, oncological, and neurodegenerative diseases.

The project concerns investments in RDI (Research, Development, and Innovation) activities, carried out by the Promoter and its partners in existing facilities without changing their already authorised scope. The project activities are not specifically covered by Annexes I or II of the EU Directive 2011/92/EU as amended by Directive 2014/52/EU and therefore is not subject to an EIA Screening or an EIA procedure.

Climate Assessment

The project has been assessed for Paris alignment and is considered to be aligned with both low-carbon and resilience goals as per the policies set out in the Climate Bank Roadmap and/or associated guidance and other relevant documents (e.g., the Energy Lending Policy).

¹ The information contained in the document reflects the requirement related to the environmental, social and climate information to be provided to Investment Committee as required by the Invest EU Regulation and it represents the equivalent of the information required in the template of the InvestEU sustainability proofing summary

² Only projects that meet the scope of the Carbon Footprint Exercise, as defined in the EIB Carbon Footprint Methodologies, are included, provided estimated emissions exceed the methodology thresholds: 20,000 tonnes CO₂e/year absolute (gross) or 20,000 tonnes CO₂e/year relative (net) – both increases and savings.



Luxembourg, June 2025

EIB Paris Alignment for Counterparties (PATH) Framework

The Promoter is in scope but screened out of the PATH framework as it does not operate in a high emitting sector and is not considered as a highly vulnerable counterpart.

Social Assessment

If successful, the project is expected to lead to important social benefits, considering the targeted indications and the level of unmet medical need.

The Promoter's R&D facilities and practices comply with relevant national and EU regulations and the Promoter maintains adequate internal procedures and management practices, especially regarding labour standards and occupational health and safety.

Other Environmental and Social Aspects

The Promoter is committed to animal welfare and the responsible use of animals for scientific purposes, ensuring that pre-clinical activities, whether performed directly or by subcontractors, comply with the European Directive 2010/63/EU on the protection of animals used for scientific purposes, where applicable.

The clinical trials are conducted in compliance with Regulation (EU) No 536/2014, where applicable, and the Promoter complies with all the legal standards of anonymisation and data protection.

Through the R&D activities and investments, the Promoter is expected to sustain its current level of skilled personnel and create additional jobs, while contributing to European scientific innovation, hence fostering and nurturing the vital research community.

Conclusions and Recommendations

The Promoter has effective E&S policies and operating procedures in place, which are in line with industry standards. The project concerns investments in research and development for which no significant impact on the environment is expected.

Sustainability proofing conclusion: the project is carried out in compliance with applicable national and EU environmental and social legislation. Based on the environment, climate and social (ECS) information and based on the review of the likely significant ECS risks and impacts and the mitigation measures and management systems in place, the project is deemed to have low residual ECS risks and impacts. No further sustainability proofing is required.

Considering the above, taking into consideration the Environmental, Social and Climate impacts of this RDI project, including the capacity of the promoter and the overall net positive social impact, this project is deemed acceptable for the Bank's financing under environmental and social terms.